Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Haffner

Showing results (111-120 of 206) with videos related to

Pageof 21
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2021
Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancerEva Shrestha, Jonathan B Coulter, William Guzman, et al.
Lab on a Chip|July 7, 2025
Lossless Altered Histone Modification Analysis System (LAHMAS)Zachary J Kauffman, Kevin Koesser, Kyle T Helzer, et al.
Oncogene|January 9, 2022
Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130Oh-Joon Kwon, Boyu Zhang, Deyong Jia, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 31, 2012
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavityMichael C Haffner, Johannes Laimer, Alcides Chaux, et al.
Cancer Research|November 1, 2008
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneitySrinivasan Yegnasubramanian, Michael C Haffner, Yonggang Zhang, et al.
Neoplasia (New York, N.Y.)|March 15, 2025
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancerAnbarasu Kumaraswamy, Rahul Mannan, Olivia A Swaim, et al.
Communications Biology|September 1, 2022
Reversible epigenetic alterations regulate class I HLA loss in prostate cancerTamara S Rodems, Erika Heninger, Charlotte N Stahlfeld, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 12, 2011
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomasAntoun Toubaji, Roula Albadine, Alan K Meeker, et al.
Cellular Oncology (Dordrecht, Netherlands)|May 30, 2020
Pervasive promoter hypermethylation of silenced TERT alleles in human cancersDavid Esopi, Mindy Kim Graham, Jacqueline A Brosnan-Cashman, et al.
Pageof 21

Showing results (111-120 of 206) with videos related to

Sort By:
Pageof 21
Proceedings of the National Academy of Sciences of the United States of America|August 3, 2021
Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancerEva Shrestha, Jonathan B Coulter, William Guzman, et al.
Lab on a Chip|July 7, 2025
Lossless Altered Histone Modification Analysis System (LAHMAS)Zachary J Kauffman, Kevin Koesser, Kyle T Helzer, et al.
Oncogene|January 9, 2022
Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130Oh-Joon Kwon, Boyu Zhang, Deyong Jia, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 31, 2012
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavityMichael C Haffner, Johannes Laimer, Alcides Chaux, et al.
Cancer Research|November 1, 2008
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneitySrinivasan Yegnasubramanian, Michael C Haffner, Yonggang Zhang, et al.
Neoplasia (New York, N.Y.)|March 15, 2025
LSD1+8a is an RNA biomarker of neuroendocrine prostate cancerAnbarasu Kumaraswamy, Rahul Mannan, Olivia A Swaim, et al.
Communications Biology|September 1, 2022
Reversible epigenetic alterations regulate class I HLA loss in prostate cancerTamara S Rodems, Erika Heninger, Charlotte N Stahlfeld, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 14, 2024
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received <sup>177</sup>Lu-PSMA-617: Importance of <sup>18</sup>F-FDG-Avid Discordant FindingsRidvan Arda Demirci, Alireza Ghodsi, Roman Gulati, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 12, 2011
Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomasAntoun Toubaji, Roula Albadine, Alan K Meeker, et al.
Cellular Oncology (Dordrecht, Netherlands)|May 30, 2020
Pervasive promoter hypermethylation of silenced TERT alleles in human cancersDavid Esopi, Mindy Kim Graham, Jacqueline A Brosnan-Cashman, et al.
Pageof 21